In the trial, Semaglutide didn’t affect total cholesterol, LDL cholesterol or blood pressure, but on an average, patients lost about 10 per cent of their body weight, which in turn reduced these risks. More research is needed for a direct correlation between the drug itself and heart health. We expect these injectables to be available in the country within a couple of years.